Published in Brain on February 01, 1994
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol (2000) 2.99
Childhood obstructive sleep apnea associates with neuropsychological deficits and neuronal brain injury. PLoS Med (2006) 1.91
Advances in white matter imaging: a review of in vivo magnetic resonance methodologies and their applicability to the study of development and aging. Neurosci Biobehav Rev (2006) 1.77
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry (2003) 1.53
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry (1999) 1.53
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol (1996) 1.39
Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging (2005) 1.36
Review: Mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol (2008) 1.25
Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx (2004) 1.23
The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci (1999) 1.21
Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am (2009) 1.17
1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry (1997) 1.16
Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One (2012) 1.16
Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications. Pediatr Radiol (2009) 1.11
Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol (1997) 1.10
Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol (2011) 1.06
White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab (2012) 1.04
Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry (2000) 1.02
Subclinical atherosclerosis is related to lower neuronal viability in middle-aged adults: a 1H MRS study. Brain Res (2010) 0.98
Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci (1999) 0.94
Investigating axonal damage in multiple sclerosis by diffusion tensor spectroscopy. J Neurosci (2012) 0.94
Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord (2013) 0.94
Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA (2002) 0.93
Balo's concentric sclerosis: a clinical case study of brain MRI, biopsy, and proton magnetic resonance spectroscopic findings. J Neurol Neurosurg Psychiatry (1997) 0.92
Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Oxid Med Cell Longev (2015) 0.92
Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry (1995) 0.92
Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 0.92
Reduction in hypothalamic 1H-MRS metabolite ratios in patients with cluster headache. J Neurol Neurosurg Psychiatry (2006) 0.92
Axon damage and repair in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci (1999) 0.90
Serial proton MR spectroscopy and diffusion tensor imaging in infantile Balo's concentric sclerosis. Neuroradiology (2008) 0.89
Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis. Eur J Neurosci (2005) 0.89
Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatry Neurol (2001) 0.87
Axonal damage in multiple sclerosis. Mt Sinai J Med (2011) 0.87
Magnetic resonance imaging of multiple sclerosis lesions. Measuring outcome in treatment trials. West J Med (1996) 0.86
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J Neurol (2007) 0.85
Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. Res Autism Spectr Disord (2014) 0.84
Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry (1999) 0.83
Advanced MRI in multiple sclerosis: current status and future challenges. Neurol Clin (2011) 0.83
Image evaluation of HIV encephalopathy: a multimodal approach using quantitative MR techniques. Neuroradiology (2011) 0.83
Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology (2009) 0.83
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy. BMC Neurol (2004) 0.82
Neuronal metabolic changes in the cortical region after subcortical infarction: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry (2000) 0.81
1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry (1998) 0.80
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. PLoS One (2016) 0.80
Magnetic resonance spectroscopy - Revisiting the biochemical and molecular milieu of brain tumors. BBA Clin (2016) 0.80
Reproducibility measurement of glutathione, GABA, and glutamate: Towards in vivo neurochemical profiling of multiple sclerosis with MR spectroscopy at 7T. J Magn Reson Imaging (2016) 0.76
Metabolic voxel-based analysis of the complete human brain using fast 3D-MRSI: Proof of concept in multiple sclerosis. J Magn Reson Imaging (2016) 0.76
Fragile X syndrome: a pilot proton magnetic resonance spectroscopy study in premutation carriers. J Neurodev Disord (2012) 0.76
Physicians, subsequence and consequence. J Neurol Neurosurg Psychiatry (1999) 0.75
Post-traumatic acute disseminated encephalomyelitis. Radiol Case Rep (2015) 0.75
Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophys Rev (2010) 0.75
The Potential of Metabolic Imaging. Semin Nucl Med (2016) 0.75
Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging. Hum Brain Mapp (2017) 0.75
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Detection and modeling of non-Gaussian apparent diffusion coefficient profiles in human brain data. Magn Reson Med (2002) 3.53
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Technique for measuring hippocampal T2 relaxation time. AJNR Am J Neuroradiol (1997) 2.65
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
The persistent vegetative state. BMJ (1995) 2.35
Management of acute optic neuritis. Lancet (2002) 2.33
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Test liquids for quantitative MRI measurements of self-diffusion coefficient in vivo. Magn Reson Med (2000) 2.14
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Biodiversity of stream insects: variation at local, basin, and regional scales. Annu Rev Entomol (1998) 2.10
The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
EEG-triggered functional MRI of interictal epileptiform activity in patients with partial seizures. Brain (1999) 1.88
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax (2005) 1.78
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73
Pathophysiology of demyelinating disease. Br Med Bull (1977) 1.70
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
The significance of the association between HLA and multiple sclerosis. Br Med Bull (1978) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med (1983) 1.62
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62